Hematology Disease Topics & Pathways:
Clinical Trials, Epidemiology, Workforce, Health Outcomes Research, Health Disparities Research, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Patient-Reported Outcomes, Real World Evidence, Registries, Study Population, Diversity, Equity, and Inclusion (DEI)
The Trials in Progress (TiP) category is for abstracts specifically describing clinical trial design without presentation of results. This abstract category is now in its 3rd year at ASH and has seen growth in the number of submissions. The purpose of the Poster Walk is to discuss innovative aspects of the trial design between the presenter, key opinion leaders, and others attending. Innovative aspects may include statistical modeling, unique endpoints, biomarkers, non-traditional control groups, and approaches for enrolling diverse participants, as well as other approaches used to streamline the clinical trial. Posters from any category below could be included and are selected from those designated as TiP abstracts by the authors at submission.
The following abstracts will be featured in this session:
Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase, Jorge Cortes
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902), Deborah Stephens
A Phase 3, Randomized, Double-Blinded Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Direct Oral Anticoagulant Therapy with Factor Xa Inhibitor: The Lex-210 Study, Ravi Sarode